ORKAMBI 100 mg/125 mg, film-coated tablet 112 tablets
Active ingredients: Ivacaftor, Lumacaftor
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet112 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ORKAMBI 100 mg/125 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 4 plaquette(s) (ACLAR RX) polytrifluorochloroéthylène PVC aluminium de 28 comprimé(s) (112 comprimés en conditionnement multiple de 4 boîtes de 28 comprimés)
- Marketing authorisation holder
- VERTEX PHARMACEUTICALS (IRELAND)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Dec 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61962699CIP73014140CIP133400930141403Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LUMACAFTORcomprimé | 100 mg · un comprimé | SA |
| IVACAFTORcomprimé | 125 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.